[ad_1]
- Experienced CFO and COO with a strong track record in the biotech and pharmaceutical industries
- Curve secures £40.5 million Series A funding, strengthens leadership team
Southampton, UK, July 9, 2024 /PRNewswire/ — Curve Therapeutics (“Curve” or the “Company”), a privately held biotechnology company pioneering the development of a revolutionary intracellular screening platform to address complex and challenging disease targets, today announced the appointment of Simon Jones Served as Chief Financial Officer (CFO) and Chief Operating Officer (COO).
Simon has over 20 years of experience in the biotech and pharmaceutical sectors. He is a seasoned executive with a broad skill set including senior operational and commercial roles in the life sciences sector, including major venture capital financings and transactions. He comes from SpyBiotech, where he led finance and operations functions during which time the company successfully advanced its lead vaccine candidate into the clinic. Previously, he served as CFO of Karus Therapeutics for nearly a decade, managing financial operations as the company secured significant financing from US and EU investors, as well as investment through the UK Government’s Future Fund scheme. Prior to this, Simon served as CFO of a number of early stage life sciences companies, including Eykona Technologies and Glide Pharmaceutical Technologies, as they transitioned from development to commercialization.
Simon KerryCurve Therapeutics CEO commented: “Simon has extensive financial experience in leadership roles at multiple clinical-stage biotech companies. His appointment comes at a critical time as we expand our team and advance our proprietary Microcycle.® discovery platforms and advance our pipeline of potential first-in-class assets.”
Simon JonesCurve Therapeutics’ Chief Financial Officer and Chief Operating Officer stated: “Curve’s revolutionary Microcycle discovery platform and rich asset pipeline mean it is a company poised to disrupt the drug discovery landscape. I am excited to join the company as it scales and transitions to become a clinical-stage company.”
Curve Therapeutics’ mission is to unlock the therapeutic potential of complex and challenging disease targets that are elusive to traditional discovery approaches. By leveraging its world-leading Microcycle discovery platform, Curve can screen directly in mammalian cells, allowing for the identification of biologically active library members in the intracellular environment, where both the library and the target are present in their native conformations. Curve is developing a small molecule dual inhibitor of HIF-1 and HIF-2 and an ATIC homodimerization inhibitor, both of which have first-in-class potential.
About Curve Therapeutics
Curve Therapeutics is a privately held biotechnology company pioneering a revolutionary intracellular screening platform to discover innovative therapeutics that address complex and challenging disease targets and have the potential to transform patients’ lives. Curve has its origins in world-leading microcirculatory research conducted by Professor Tavassoli’s team at the Department of Chemistry at the University of Southampton, UK. Curve is backed by blue chip investors including Advent Life Sciences, Epidarex Capital, Pfizer Ventures, Columbus Venture Partners and British Patient Capital. Curve has $1.7 billion A global research collaboration with Merck & Co., Inc. under the trade name MSD Kenilworth, New Jersey US-based company uses its microcirculation technology to discover and validate modulators of up to five therapeutic targets, initially for oncology and neurology indications. For more information, visit: www.curvetx.com.
About Curve’s Microcycle Platform
Curve has developed an IP-protected mammalian cell platform technology for functional screening and enrichment of diverse hexameric peptide minicircle libraries to identify those library members that possess desired bioactivity against therapeutic targets. Curve’s platform allows for direct screening of library members for bioactivity within mammalian cells and facilitates small molecule hit-to-lead programs. A key advantage of the technology is that both the library and the target exist in all native conformations within the cell. Uniquely, the compact size and rigid structure of the minicircles enable the design of non-peptide small molecule leads. The platform can be used for a wide range of therapeutically relevant targets, including protein-protein and protein-DNA interactions, and has been used by Curve to develop a range of cancer programs against targets, including dual HIF-1/HIF-2 inhibitors and ATIC homodimerization inhibitors.
SOURCE Curve Therapeutics
[ad_2]
Source link
